Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Restless Leg Syndrome and Night Terrors

Restless Leg Syndrome and Night Terrors

Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A comprehensive assessment of lifecourse and mortality of Parkinson's disease in the German National Cohort.

NPJ Parkinson's disease·2026

Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026

Same author

Genetic Testing by Age at Onset in Parkinson Disease.

JAMA neurology·2026

Same author

Temporal dynamics of cognitive functioning in people with Parkinson's disease.

NPJ Parkinson's disease·2026

Same author

MDS Global Survey on Work Environment, Career Advancement, and Work-Life Balance in Movement Disorders Professionals: Gender and Regional Patterns.

Movement disorders clinical practice·2026

Same author

Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders.

medRxiv : the preprint server for health sciences·2026

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Levodopa for restless legs syndrome.

Hanna Scholz¹, Claudia Trenkwalder, Ralf Kohnen

¹Interdisciplinary Pain Canter, University Medical Center, Freiburg, Breisacher Strasse, 64, Freiburg, Germany, 79106.

The Cochrane Database of Systematic Reviews

|February 18, 2011

Summary

This summary is machine-generated.

Levodopa effectively reduces restless legs syndrome (RLS) symptoms and improves sleep quality in the short term. However, more research is needed on augmentation, a significant adverse event.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: Jun 4, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Neurology
Pharmacology
Sleep Medicine

Background:

Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move the legs.
Levodopa, often combined with a dopamine decarboxylase inhibitor, is a common pharmacological intervention for RLS.

Purpose of the Study:

To systematically evaluate the efficacy and safety of levodopa for treating RLS.
To compare levodopa's effects against placebo and other active treatments.

Main Methods:

A comprehensive literature search was conducted across multiple databases (CENTRAL, MEDLINE, EMBASE, PsycINFO, CINAHL) from 1985 to 2008.
Included were double-blind randomized controlled trials (RCTs) of at least seven days duration in adult RLS patients, comparing levodopa to placebo or active agents.
Outcomes assessed included symptom severity, clinical global impression, sleep parameters, quality of life, and safety.

Main Results:

Levodopa significantly reduced RLS symptom severity (MD -1.34) and periodic limb movements in sleep (PLMS-Index improved by -26.28/h) compared to placebo.
Improvements were also observed in clinical global impression (MD -1.25), sleep quality (SMD 0.92), and quality of life (3.23) versus placebo.
While few patients discontinued due to adverse events, more levodopa-treated patients experienced them (OR 2.61). Levodopa showed smaller effects than cabergoline and pramipexole in active-controlled studies.

Conclusions:

Levodopa demonstrates short-term efficacy in managing restless legs syndrome symptoms and improving sleep.
The potential for augmentation, a critical adverse event in RLS treatment, requires further investigation.
Levodopa may be less effective than certain dopamine agonists for RLS treatment.